Literature DB >> 18041878

Metabolic syndrome and mental illness.

John W Newcomer1.   

Abstract

Patients with mental illnesses such as schizophrenia and bipolar disorder have an increased prevalence of metabolic syndrome and its components, risk factors for cardiovascular disease and type 2 diabetes. Although the prevalence of obesity and other risk factors such as hyperglycemia are increasing in the general population, patients with major mental illnesses have an increased prevalence of overweight and obesity, hyperglycemia, dyslipidemia, hypertension, and smoking, and substantially greater mortality, compared with the general population. Persons with major mental disorders lose 25 to 30 years of potential life in comparison with the general population, primarily due to premature cardiovascular mortality. The causes of increased cardiometabolic risk in this population can include nondisease-related factors such as poverty and reduced access to medical care, as well as adverse metabolic side effects associated with psychotropic medications, such as antipsychotic drugs. Individual antipsychotic medications are associated with well-defined risks of weight gain and related risks for adverse changes in glucose and lipid metabolism. Based on the medical risk profile of persons with major mental illnesses, and the evidence that certain medications can contribute to increased risk, screening and regular monitoring of metabolic parameters such as weight (body mass index), waist circumference, plasma glucose and lipids, and blood pressure are recommended to manage risk in this population. Treatment decisions should incorporate information about medical risk factors in general and cardiometabolic risk in particular. In addition to the implications for individual clinicians, the problem of disparity in meeting healthcare needs for persons with mental illness in comparison with the general population has become an important public policy concern, with recent recommendations from the National Association of State Mental Health Program Directors and the Institute of Medicine. This article provides an overview of cardiometabolic risk in patients with major mental illness and describes steps for risk reduction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18041878

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  55 in total

1.  Exercise program adherence using a 5-kilometer (5K) event as an achievable goal in people with schizophrenia.

Authors:  Kimberly R Warren; M Patricia Ball; Stephanie Feldman; Fang Liu; Robert P McMahon; Deanna L Kelly
Journal:  Biol Res Nurs       Date:  2010-12-30       Impact factor: 2.522

2.  Olanzapine metabolic side effects: a weight gain issue?

Authors:  Lucia Carulli; Fausto Mazzi; Stefania Rondinella; Marco Bertolotti
Journal:  Intern Emerg Med       Date:  2008-03-28       Impact factor: 3.397

3.  Can anti-inflammatory medications improve symptoms and reduce mortality in schizophrenia?

Authors:  Maju Mathew Koola; Jeffrey K Raines; Robert G Hamilton; Robert P McMahon
Journal:  Curr Psychiatr       Date:  2016-04-25

4.  Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.

Authors:  Lawrence S Kegeles; Mark Slifstein; Xiaoyan Xu; Nina Urban; Judy L Thompson; Tiffany Moadel; Jill M Harkavy-Friedman; Roberto Gil; Marc Laruelle; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2010-07-31       Impact factor: 13.382

5.  Metabolic syndrome in people with schizophrenia: a review.

Authors:  Marc DE Hert; Vincent Schreurs; Davy Vancampfort; Ruud VAN Winkel
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

6.  Gender differences in the association between body mass index and psychopathology.

Authors:  Rani A Desai; Melinda Manley; Mayur M Desai; Marc N Potenza
Journal:  CNS Spectr       Date:  2009-07       Impact factor: 3.790

7.  Sex difference in the association of body mass index and BDNF levels in Chinese patients with chronic schizophrenia.

Authors:  Fang Yang; Keming Wang; Xiangdong Du; Huiqiong Deng; Hanjing Emily Wu; Guangzhong Yin; Yuping Ning; Xingbing Huang; Antonio L Teixeira; João de Quevedo; Jair C Soares; Xiaosi Li; XiaoE Lang; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2018-11-19       Impact factor: 4.530

8.  Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration.

Authors:  Lizheng Shi; Haya Ascher-Svanum; Yi-Ju Chiang; Yingnan Zhao; Vivian Fonseca; Daniel Winstead
Journal:  BMC Psychiatry       Date:  2009-12-18       Impact factor: 3.630

9.  Emerging role of sertindole in the management of schizophrenia.

Authors:  Stephanie L Cincotta; Joshua S Rodefer
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

10.  Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.

Authors:  David C Henderson; Xiaoduo Fan; Bikash Sharma; Paul M Copeland; Christina P C Borba; Oliver Freudenreich; Corinne Cather; A Eden Evins; Donald C Goff
Journal:  J Psychiatr Pract       Date:  2009-07       Impact factor: 1.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.